From Paragraph IV certifications to 30-month stays, Orange Book listings to authorized generics — a practitioner’s guide to the law […]

Pharmaceutical pipeline valuations collapse fastest not at clinical failure, but at patent expiry. The day a branded generic crosses the

What this article covers: How to read the FDA Orange Book like a competitive intelligence tool, not a regulatory checkbox.

Every drug company CFO knows the number. The day their new chemical entity (NCE) exclusivity expires is circled, starred, and

When a blockbuster drug’s patent expires, the originator company faces a choice that will define its revenue trajectory for the

Two federal statutes govern most of what happens when a pharmaceutical patent expires in the United States. One dates to

Every year, billions of dollars in branded drug revenue evaporate on a single day: the day a generic or branded

AbbVie held Humira’s U.S. market alone for twenty years. Not because it held one brilliant patent, but because it built

Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a